Thrivent Financial for Lutherans Buys 14,444 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Thrivent Financial for Lutherans boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 639,332 shares of the biotechnology company's stock after purchasing an additional 14,444 shares during the period. Thrivent Financial for Lutherans owned about 0.67% of Sarepta Therapeutics worth $77,736,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SRPT. Corient Private Wealth LLC bought a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $786,000. CBIZ Investment Advisory Services LLC increased its position in Sarepta Therapeutics by 163.2% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 587 shares of the biotechnology company's stock worth $71,000 after buying an additional 364 shares during the period. Commonwealth Equity Services LLC lifted its holdings in shares of Sarepta Therapeutics by 22.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company's stock worth $773,000 after buying an additional 1,151 shares in the last quarter. Erste Asset Management GmbH boosted its position in shares of Sarepta Therapeutics by 11.3% in the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company's stock valued at $86,116,000 after acquiring an additional 72,183 shares during the period. Finally, Swiss National Bank grew its stake in shares of Sarepta Therapeutics by 1.6% in the fourth quarter. Swiss National Bank now owns 168,783 shares of the biotechnology company's stock valued at $20,522,000 after acquiring an additional 2,700 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Sarepta Therapeutics Price Performance

SRPT stock traded up $0.65 during midday trading on Friday, reaching $74.10. 2,591,321 shares of the stock were exchanged, compared to its average volume of 1,218,291. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $7.19 billion, a PE ratio of 59.28 and a beta of 0.79. Sarepta Therapeutics, Inc. has a 52 week low of $73.05 and a 52 week high of $173.25. The company has a fifty day moving average price of $107.19 and a 200 day moving average price of $118.00.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.70% of the company's stock.

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of recent research reports. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. HC Wainwright restated a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a report on Thursday. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $167.41.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.